Abstract
522 - A Phase 1 Study Evaluating Safety and Efficacy of Parsaclisib in Combination with Bendamustine + Obinutuzumab in Patients with Relapsed or Refractory Follicular Lymphoma (R/R FL) (CITADEL-102)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have